(ZEG) AstraZeneca - Ratings and Ratios
Oncology, Cardiovascular, Respiratory, Immunology, Rare Diseases
Dividends
| Dividend Yield | 2.07% |
| Yield on Cost 5y | 4.25% |
| Yield CAGR 5y | 1.97% |
| Payout Consistency | 94.8% |
| Payout Ratio | 51.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 23.3% |
| Value at Risk 5%th | 34.4% |
| Relative Tail Risk | -10.23% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.74 |
| Alpha | 19.89 |
| CAGR/Max DD | 0.28 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.565 |
| Beta | -0.118 |
| Beta Downside | 0.225 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.22% |
| Mean DD | 10.10% |
| Median DD | 9.73% |
Description: ZEG AstraZeneca December 01, 2025
AstraZeneca PLC (XETRA:ZEG) is a global biopharmaceutical firm headquartered in Cambridge, UK, that discovers, develops, manufactures, and commercializes prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines, and rare diseases. Its product portfolio includes flagship oncology agents such as Tagrisso, Imfinzi and Lynparza, as well as leading cardiovascular drugs like Farxiga and Brilinta, and respiratory treatments including Symbicort and Breztri. The company reaches physicians through distributors and local offices in the UK, US, Europe, and Asia, and it maintains strategic collaborations with Tempus (AI-driven oncology models), IonQ (quantum-accelerated chemistry), CSPC (oral candidate discovery), and Revna Biosciences (lung cancer).
Key recent metrics: FY 2023 revenue reached £26.1 bn, with R&D spending of £5.5 bn (≈21% of sales), and Tagrisso generated $2.6 bn in Q4 2023 sales, underscoring oncology’s outsized contribution to growth. The sector’s mid-term drivers-an aging global population, expanding immuno-oncology indications, and a 6-8% CAGR in the oncology market-support AstraZeneca’s pipeline focus. However, the firm faces pricing pressure in the US and potential patent expirations in its cardiovascular franchise, which could temper margin expansion.
For a deeper quantitative assessment, you might explore the ValueRay platform’s analyst-grade metrics on ZEG.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (9.40b TTM) > 0 and > 6% of Revenue (6% = 3.49b TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 2.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -7.08% (prev -3.46%; Δ -3.62pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 15.14b > Net Income 9.40b (YES >=105%, WARN >=100%) |
| Net Debt (24.52b) to EBITDA (17.98b) ratio: 1.36 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.56b) change vs 12m ago -0.06% (target <= -2.0% for YES) |
| Gross Margin 82.28% (prev 80.88%; Δ 1.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.99% (prev 48.80%; Δ 4.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.27 (EBITDA TTM 17.98b / Interest Expense TTM 1.57b) >= 6 (WARN >= 3) |
Altman Z'' 0.95
| (A) -0.04 = (Total Current Assets 29.94b - Total Current Liabilities 34.05b) / Total Assets 114.46b |
| (B) 0.07 = Retained Earnings (Balance) 8.21b / Total Assets 114.46b |
| (C) 0.12 = EBIT TTM 12.95b / Avg Total Assets 109.69b |
| (D) 0.16 = Book Value of Equity 10.64b / Total Liabilities 68.48b |
| Total Rating: 0.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 86.48
| 1. Piotroski 8.50pt |
| 2. FCF Yield 3.48% |
| 3. FCF Margin 18.25% |
| 4. Debt/Equity 0.71 |
| 5. Debt/Ebitda 1.36 |
| 6. ROIC - WACC (= 8.73)% |
| 7. RoE 21.80% |
| 8. Rev. Trend 87.65% |
| 9. EPS Trend 78.42% |
What is the price of ZEG shares?
Over the past week, the price has changed by -1.37%, over one month by +3.38%, over three months by +11.92% and over the past year by +23.26%.
Is ZEG a buy, sell or hold?
What are the forecasts/targets for the ZEG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 147.9 | -4.2% |
ZEG Fundamental Data Overview December 10, 2025
Market Cap USD = 280.24b (240.76b EUR * 1.164 EUR.USD)
P/E Trailing = 30.0387
P/E Forward = 16.5563
P/S = 4.1419
P/B = 6.1259
P/EG = 0.9804
Beta = 0.168
Revenue TTM = 58.13b USD
EBIT TTM = 12.95b USD
EBITDA TTM = 17.98b USD
Long Term Debt = 24.70b USD (from longTermDebt, last quarter)
Short Term Debt = 6.58b USD (from shortTermDebt, last quarter)
Debt = 32.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 24.52b USD (from netDebt column, last quarter)
Enterprise Value = 304.72b USD (280.24b + Debt 32.66b - CCE 8.18b)
Interest Coverage Ratio = 8.27 (Ebit TTM 12.95b / Interest Expense TTM 1.57b)
FCF Yield = 3.48% (FCF TTM 10.61b / Enterprise Value 304.72b)
FCF Margin = 18.25% (FCF TTM 10.61b / Revenue TTM 58.13b)
Net Margin = 16.17% (Net Income TTM 9.40b / Revenue TTM 58.13b)
Gross Margin = 82.28% ((Revenue TTM 58.13b - Cost of Revenue TTM 10.30b) / Revenue TTM)
Gross Margin QoQ = 81.16% (prev 82.89%)
Tobins Q-Ratio = 2.66 (Enterprise Value 304.72b / Total Assets 114.46b)
Interest Expense / Debt = 1.07% (Interest Expense 349.0m / Debt 32.66b)
Taxrate = 21.86% (709.0m / 3.24b)
NOPAT = 10.12b (EBIT 12.95b * (1 - 21.86%))
Current Ratio = 0.88 (Total Current Assets 29.94b / Total Current Liabilities 34.05b)
Debt / Equity = 0.71 (Debt 32.66b / totalStockholderEquity, last quarter 45.89b)
Debt / EBITDA = 1.36 (Net Debt 24.52b / EBITDA 17.98b)
Debt / FCF = 2.31 (Net Debt 24.52b / FCF TTM 10.61b)
Total Stockholder Equity = 43.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.21% (Net Income 9.40b / Total Assets 114.46b)
RoE = 21.80% (Net Income TTM 9.40b / Total Stockholder Equity 43.11b)
RoCE = 19.09% (EBIT 12.95b / Capital Employed (Equity 43.11b + L.T.Debt 24.70b))
RoIC = 13.81% (NOPAT 10.12b / Invested Capital 73.23b)
WACC = 5.08% (E(280.24b)/V(312.90b) * Re(5.58%) + D(32.66b)/V(312.90b) * Rd(1.07%) * (1-Tc(0.22)))
Discount Rate = 5.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 80.01% ; FCFE base≈9.07b ; Y1≈10.28b ; Y5≈14.03b
Fair Price DCF = 156.7 (DCF Value 242.86b / Shares Outstanding 1.55b; 5y FCF grow 15.61% → 3.0% )
EPS Correlation: 78.42 | EPS CAGR: 113.8% | SUE: N/A | # QB: 0
Revenue Correlation: 87.65 | Revenue CAGR: 6.46% | SUE: N/A | # QB: 0